GeneMatrix Inc Net Assets

Latest as of September 2025: ₩18.32 Billion KRW ≈ $12.41 Million USD

GeneMatrix Inc net assets. Based on the latest financial reports, GeneMatrix Inc (109820) has net assets worth ₩18.32 Billion KRW (≈ $12.41 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩28.03 Billion ≈ $19.00 Million USD) and total liabilities (₩9.72 Billion ≈ $6.59 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore GeneMatrix Inc equity growth rate to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩18.32 Billion
% of Total Assets	65.33%
Annual Growth Rate	1.55%
5-Year Change	-42.42%
10-Year Change	91.56%
Growth Volatility	36.7

Net Assets of GeneMatrix Inc (2011–2024)

Net assets of GeneMatrix Inc from 2011 to 2024. This chart illustrates how GeneMatrix Inc's net assets have evolved over time, based on quarterly financial data. See GeneMatrix Inc balance sheet quality to measure how much of total assets are equity-financed.

Annual Net Assets for GeneMatrix Inc (2011–2024)

The table below shows the annual net assets of GeneMatrix Inc from 2011 to 2024. For live market cap and overall valuation, see market cap of GeneMatrix Inc.

Year	Net Assets	Change
2024-12-31	₩19.23 Billion ≈ $13.03 Million	-16.94%
2023-12-31	₩23.15 Billion ≈ $15.69 Million	-4.29%
2022-12-31	₩24.19 Billion ≈ $16.39 Million	-25.17%
2021-12-31	₩32.32 Billion ≈ $21.90 Million	-3.21%
2020-12-31	₩33.39 Billion ≈ $22.63 Million	+118.98%
2019-12-31	₩15.25 Billion ≈ $10.33 Million	+40.76%
2018-12-31	₩10.83 Billion ≈ $7.34 Million	-2.04%
2017-12-31	₩11.06 Billion ≈ $7.49 Million	-11.41%
2016-12-31	₩12.48 Billion ≈ $8.46 Million	+24.37%
2015-12-31	₩10.04 Billion ≈ $6.80 Million	-15.57%
2014-12-31	₩11.89 Billion ≈ $8.06 Million	-6.98%
2013-12-31	₩12.78 Billion ≈ $8.66 Million	-8.18%
2012-12-31	₩13.92 Billion ≈ $9.43 Million	-11.57%
2011-12-31	₩15.74 Billion ≈ $10.67 Million	--

Equity Component Analysis

This analysis shows how different components contribute to GeneMatrix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 2144663611000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

GeneMatrix Inc Net Assets Breakdown (December 2024)

GeneMatrix Inc net assets breakdown by equity component as of December 2024.

Component	Amount	Percentage
Common Stock	₩10.20 Billion	53.03%
Other Components	₩30.48 Billion	158.51%
Total Equity	₩19.23 Billion	100.00%

GeneMatrix Inc Competitors by Market Cap

The table below lists competitors of GeneMatrix Inc ranked by their market capitalization.

Company	Market Cap
Australian Rare EARTHS Ltd AU:AR3	$18.99 Million
Softcen Co. Ltd KQ:032680	$18.99 Million
High-Tech Metals Ltd AU:HTM	$19.00 Million
Law Debenture Corp LSE:LWDB	$19.00 Million
STS Group AG XETRA:SF3	$18.96 Million
Hubei Geoway Investment Co Ltd SHG:600462	$18.96 Million
Shenzhen Tellus Holding Co Ltd SHE:200025	$18.96 Million
The Beachbody Company, Inc. NASDAQ:BODI	$18.95 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in GeneMatrix Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 23,148,242,030 to 19,227,336,450, a change of -3,920,905,580 (-16.9%).
Net loss of 3,748,057,580 reduced equity.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	₩-3.75 Billion	-19.49%
Other Changes	₩-172.85 Million	-0.9%
Total Change	₩-	-16.94%

Book Value vs Market Value Analysis

This analysis compares GeneMatrix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.46x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 1.72x to 1.46x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	₩814.65	₩1403.00	x
2017-12-31	₩721.74	₩1403.00	x
2018-12-31	₩675.66	₩1403.00	x
2019-12-31	₩845.72	₩1403.00	x
2020-12-31	₩1672.63	₩1403.00	x
2021-12-31	₩1618.95	₩1403.00	x
2022-12-31	₩1211.46	₩1403.00	x
2023-12-31	₩1159.49	₩1403.00	x
2024-12-31	₩963.09	₩1403.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently GeneMatrix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -19.49%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -37.41%
• Asset Turnover: 0.35x
• Equity Multiplier: 1.48x
Recent ROE (-19.49%) is below the historical average (-13.76%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2014	-10.98%	-16.82%	0.39x	1.67x	₩-2.15 Billion
2015	-23.28%	-38.01%	0.26x	2.40x	₩-2.89 Billion
2016	-30.26%	-74.35%	0.26x	1.55x	₩-5.03 Billion
2017	-13.29%	-28.32%	0.29x	1.60x	₩-2.58 Billion
2018	-28.68%	-65.61%	0.15x	2.91x	₩-4.19 Billion
2019	-8.96%	-27.06%	0.18x	1.87x	₩-2.89 Billion
2020	24.05%	50.50%	0.42x	1.14x	₩4.69 Billion
2021	-3.06%	-8.16%	0.31x	1.22x	₩-4.22 Billion
2022	-33.54%	-72.33%	0.35x	1.32x	₩-10.53 Billion
2023	-3.87%	-9.12%	0.31x	1.35x	₩-3.21 Billion
2024	-19.49%	-37.41%	0.35x	1.48x	₩-5.67 Billion

Industry Comparison

This section compares GeneMatrix Inc's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

Industry: Diagnostics & Research
Average net assets among peers: $97,102,205,854
Average return on equity (ROE) among peers: -20.95%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
GeneMatrix Inc (109820)	₩18.32 Billion	-10.98%	0.53x	$18.98 Million
NSN Co. Ltd (031860)	$51.00 Billion	-27.70%	0.20x	$12.68 Million
JOONGANG DNM Co.Ltd (051980)	$42.13 Billion	-34.73%	0.45x	$498.88 Million
Genoray Co. Ltd (122310)	$95.53 Billion	13.07%	0.30x	$24.78 Million
Green Cross Lab Cell Corporation (144510)	$511.00 Billion	6.15%	0.26x	$102.86 Million
Optipharm.CO.LTD (153710)	$13.50 Billion	-2.58%	0.52x	$42.20 Million
Cancer Rop Co. Ltd. (180400)	$34.91 Billion	-15.37%	0.94x	$121.40 Million
Cytogen Inc (217330)	$17.92 Billion	-23.11%	0.10x	$36.19 Million
Gencurix Inc (229000)	$30.99 Billion	-111.87%	0.78x	$31.07 Million
P&K Skin Research Center Co. Ltd (347740)	$76.94 Billion	7.56%	0.07x	$35.45 Million

About GeneMatrix Inc

KQ:109820 Korea Diagnostics & Research

Market Cap

$18.98 Million

₩28.01 Billion KRW

Market Cap Rank

#25136 Global

#1844 in Korea

Share Price

₩1403.00

Change (1 day)

-1.13%

52-Week Range

₩1314.00 - ₩2545.00

All Time High

₩33900.00